Evidence map›Paper›PMID 34778029›Full record

ArticleFrontiers in oncology2021

Post-Induction Management in Patients With Left-Sided

Alessandro Parisi, Alessio Cortellini, Olga Venditti, Roberto Filippi, Lisa Salvatore, Giampaolo Tortora, Michele Ghidini, Olga Nigro, Fabio Gelsomino, Ina Valeria Zurlo and 21 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 20 institutions in 3 countries.

Alessandro ParisiMedical Oncology, St. Salvatore Hospital, L'Aquila, Italy.
Alessio CortelliniDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Olga VendittiMedical Oncology, St. Salvatore Hospital, L'Aquila, Italy.
Roberto FilippiDepartment of Oncology, University of Turin, Turin, Italy.
Lisa SalvatoreUniversità Cattolica del Sacro Cuore, Rome, Italy.
Giampaolo TortoraUniversità Cattolica del Sacro Cuore, Rome, Italy.
Michele GhidiniMedical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Olga NigroMedical Oncology, ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
Fabio GelsominoDepartment of Oncology and Hematology, Division of Oncology, University Hospital of Modena, Modena, Italy.
Ina Valeria ZurloMedical Oncology, "Vito Fazzi" Hospital, Lecce, Italy.
Claudia FulgenziMedical Oncology, Campus Bio-Medico, University of Rome, Rome, Italy.
Pasquale LombardiDivision of Medical Oncology, Candiolo Cancer Institute, Fondazione Del Piemonte Per L'oncologia-Istiruto di Ricerca e Cura a Carattere Scientifico (FPO-IRCCS), Candiolo, Italy.
Susana Roselló KeränenDepartment of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
Ilaria DepetrisMedical Oncology, ASL TO4, Ospedale Civile di Ivrea, Turin, Italy.
Riccardo GiampieriClinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, AOU Ospedali Riuniti-Ancona, Ancona, Italy.
Cristina MorelliMedical Oncology Unit and PhD Program in Systems and Experimental Medicine (XXXV cycle), Tor Vergata University Hospital, Rome, Italy.
Pietro Di MarinoDepartment of Medical, Oral and Biotechnological Sciences and Center for Advance Studies and Technology (CAST), G. D'Annunzio University, Chieti, Italy.
Francesca Romana Di PietroIRCCS Istituto Dermopatico dell'Immacolata (IDI), Rome, Italy.
Nicoletta ZanalettiExperimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G.Pascale, Naples, Italy.
Pasquale VitaleDepartment of Precision Medicine, Università della Campania "Luigi Vanvitelli", Naples, Italy.
Ingrid GarajovaMedical Oncology Unit, University Hospital of Parma, Parma, Italy.
Gian Paolo SpinelliUOC Territorial Oncology-AUSL Latina-CdS Aprilia-University of Rome "Sapienza", Rome, Italy.
Federica ZorattoMedical Oncology, Santa Maria Goretti Hospital, Latina, Italy.
Michela RobertoDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, Oncology Unit, Sant'Andrea Hospital, Rome, Italy.
Angelica PetrilloMedical Oncology Unit, Ospedale del Mare, Naples, Italy.
Giacomo AimarDepartment of Oncology, University of Turin, Turin, Italy.
Leonardo PatrunoMedical Oncology, St. Salvatore Hospital, L'Aquila, Italy.
Carla D'OrazioMedical Oncology, St. Salvatore Hospital, L'Aquila, Italy.
Corrado FicorellaMedical Oncology, St. Salvatore Hospital, L'Aquila, Italy.
Claudio FerriDepartment of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
Giampiero PorzioMedical Oncology, St. Salvatore Hospital, L'Aquila, Italy.
San Salvatore Hospital · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITSapienza University of Rome · ITUniversity of L'Aquila · ITAgostino Gemelli University Polyclinic · ITCandiolo Cancer Institute · ITCentro de Investigación Biomédica en Red de Cáncer · ESFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITImperial College London · GBIstituto Dermopatico dell'Immacolata · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITMarche Polytechnic University · ITOspedale Civile Di Ivrea · ITOspedale di Circolo e Fondazione Macchi · ITOspedale Santa Maria Goretti · ITOspedale SS. Annunziata · ITOspedale Vito Fazzi · ITUniversità Campus Bio-Medico · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Campania "Luigi Vanvitelli" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFew data regarding post-induction management following first-line anti-epidermal growth factor receptor (EGFR)-based doublet regimens in patients with left-sided

methodsThis multicenter, retrospective study aimed at evaluating clinicians' attitude, and the safety and effectiveness of post-induction strategies in consecutive patients affected by left-sided

resultsAt the data cutoff, among 686 consecutive patients with left-sided

conclusionAmong the treatment strategies following an anti-EGFR-based doublet first-line induction regimen in patients affected by left-sided

Indexed as

cetuximabFOLFIRIFOLFOXmaintenanceMCRCobservation, de-escalationpanitumumab

Identifiers

PMID34778029
PMCPMC8579084
OpenAlexW3208855266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.